Increased serum concentration of netrin-1 after intravitreal bevacizumab injection: is it a compensatory mechanism to counteract drug side effects?

Table 4 Intra-group comparison of netrin-1 and vascular endothelial growth factor concentrations before and one week and one month after the injection of bevacizumab

		Baseline netrin-1 (pg/ml)	1 week netrin-1 (pg/ml)	1 month netrin-1 (pg/ml)	P-value	Baseline VEGF (pg/ml)	1 week VEGF (pg/ml)	1 month VEGF (pg/ml)	P-value
NPDR group	mean ± SD	252.7±74.6	416.3±123.0	747.5±89.6	< 0.0001^a	196.9±78.2	150.23±96.23	76.46±53.91	< 0.002^a
NPDR group	median (IQR)	245,5 (213,8-324,8)	398,5 (317,3-456,6)	743,7 (689,7-827,6)	< 0.0001^a	184,3 (155,6-221,8)	131,15 (87,40-187,50)	50,78 (41,40-98,50)	< 0.002^a
PDR group	mean ± SD	318.2±68.4	476,6±225.0	676.6±187.5	< 0.0001^a	388.4±232.4	193.41±89.13	97.89±53.08	< 0.0001^a
PDR group	median (IQR)	300,5 (272,5-300,5)	377,0 (371,3-377,0)	719,7 (579,7-719,7)	< 0.0001^a	319,5 (288,8-319,5)	161,20 (146,10-161,20)	83,34 (67,50-83,34)	< 0.0001^a

VEGF Vascular endothelial growth factor, IQR Interquartile range, SD Standard deviation, NPDR non-proliferative diabetic retinopathy, PDR Proliferative diabetic retinopathy
Note: ^aFriedman test

ISSN: 1471-2415